Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -282.52 Million CNY | -43.12% |
| 2022 | -197.4 Million CNY | -62.54% |
| 2021 | -121.45 Million CNY | 69.78% |
| 2020 | -401.82 Million CNY | -17.77% |
| 2019 | -341.18 Million CNY | -8.46% |
| 2018 | -314.57 Million CNY | -0.92% |
| 2017 | -311.72 Million CNY | -44.19% |
| 2016 | -216.19 Million CNY | -24.61% |
| 2015 | -173.49 Million CNY | -43.88% |
| 2014 | -120.58 Million CNY | 23.93% |
| 2013 | -158.51 Million CNY | 2.37% |
| 2012 | -162.36 Million CNY | -7.76% |
| 2011 | -150.67 Million CNY | -385.17% |
| 2010 | -31.05 Million CNY | -138.51% |
| 2009 | 80.63 Million CNY | -58.48% |
| 2008 | 194.22 Million CNY | 64.11% |
| 2007 | 118.35 Million CNY | 27.21% |
| 2006 | 93.03 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -222.54 Million CNY | -156.89% |
| 2024 Q1 | 382.2 Million CNY | 235.28% |
| 2023 Q2 | -145.5 Million CNY | -141.56% |
| 2023 Q4 | -282.52 Million CNY | -189.0% |
| 2023 Q3 | 317.44 Million CNY | 318.17% |
| 2023 FY | -282.52 Million CNY | -43.12% |
| 2023 Q1 | 350.09 Million CNY | 277.35% |
| 2022 Q2 | -193.99 Million CNY | -162.35% |
| 2022 Q4 | -197.4 Million CNY | -160.02% |
| 2022 FY | -197.4 Million CNY | -62.54% |
| 2022 Q1 | 311.14 Million CNY | 356.19% |
| 2022 Q3 | 328.89 Million CNY | 269.54% |
| 2021 Q2 | -221.19 Million CNY | -153.19% |
| 2021 Q1 | 415.88 Million CNY | 203.5% |
| 2021 FY | -121.45 Million CNY | 69.78% |
| 2021 Q4 | -121.45 Million CNY | 0.0% |
| 2020 Q2 | -185.03 Million CNY | -148.16% |
| 2020 FY | -401.82 Million CNY | -17.77% |
| 2020 Q1 | 384.21 Million CNY | 212.61% |
| 2020 Q4 | -401.82 Million CNY | 0.0% |
| 2019 Q1 | 323.57 Million CNY | 202.86% |
| 2019 Q2 | -244.82 Million CNY | -175.66% |
| 2019 Q4 | -341.18 Million CNY | 0.0% |
| 2019 FY | -341.18 Million CNY | -8.46% |
| 2018 Q2 | -113.41 Million CNY | -132.34% |
| 2018 FY | -314.57 Million CNY | -0.92% |
| 2018 Q4 | -314.57 Million CNY | 0.0% |
| 2018 Q1 | 350.72 Million CNY | 212.51% |
| 2017 Q2 | -181.24 Million CNY | -155.06% |
| 2017 Q1 | 329.19 Million CNY | 252.27% |
| 2017 FY | -311.72 Million CNY | -44.19% |
| 2017 Q4 | -311.72 Million CNY | 0.0% |
| 2016 Q4 | -216.19 Million CNY | 0.0% |
| 2016 Q1 | 300.1 Million CNY | 272.98% |
| 2016 FY | -216.19 Million CNY | -24.61% |
| 2016 Q2 | -144.32 Million CNY | -148.09% |
| 2015 Q2 | -139.2 Million CNY | -151.37% |
| 2015 Q4 | -173.49 Million CNY | 0.0% |
| 2015 Q1 | 270.95 Million CNY | 324.7% |
| 2015 FY | -173.49 Million CNY | -43.88% |
| 2014 FY | -120.58 Million CNY | 23.93% |
| 2014 Q2 | -138.59 Million CNY | -154.24% |
| 2014 Q4 | -120.58 Million CNY | 0.0% |
| 2014 Q1 | 255.51 Million CNY | 261.19% |
| 2013 Q2 | -130.76 Million CNY | -152.65% |
| 2013 FY | -158.51 Million CNY | 2.37% |
| 2013 Q4 | -158.51 Million CNY | 0.0% |
| 2013 Q1 | 248.36 Million CNY | 252.97% |
| 2012 FY | -162.36 Million CNY | -7.76% |
| 2012 Q4 | -162.36 Million CNY | 0.0% |
| 2012 Q2 | -139.06 Million CNY | 0.0% |
| 2011 Q2 | -33.24 Million CNY | 0.0% |
| 2011 Q4 | -150.67 Million CNY | 0.0% |
| 2011 FY | -150.67 Million CNY | -385.17% |
| 2010 Q2 | 159.18 Million CNY | 0.0% |
| 2010 FY | -31.05 Million CNY | -138.51% |
| 2010 Q4 | -31.05 Million CNY | 0.0% |
| 2009 Q4 | 80.63 Million CNY | 0.0% |
| 2009 FY | 80.63 Million CNY | -58.48% |
| 2008 FY | 194.22 Million CNY | 64.11% |
| 2007 FY | 118.35 Million CNY | 27.21% |
| 2006 FY | 93.03 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | -9.206% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 113.905% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 4853.028% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 193.694% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -1383.979% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 1012.886% |
| Essex Bio-Technology Limited | -219.22 Million HKD | -28.87% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 210.289% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 174.83% |
| SSY Group Limited | 1.71 Billion HKD | 116.488% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -3718.354% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 183.724% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 100.554% |